ALX-0171
Drug
ABLYNX NV
Total Payments
$100,958
Transactions
8
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $100,958 | 8 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $100,958 | 8 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A randomized, double-blind, multicenter study to evaluate the efficacy and safety of ALX-0171 versus placebo, in addition to standard of care, in adults who have undergone hematopoietic stem cell tran | ABLYNX NV | $92,458 | 0 |
| A Randomized, Double-blind, Placebo-controlled, Multicenter Dose Ranging Study of ALX-0171 in Infants and Young Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection | ABLYNX NV | $8,500 | 0 |
Top Doctors Receiving Payments for ALX-0171
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cleveland, OH | $100,958 | 8 |
About ALX-0171
ALX-0171 is a drug associated with $100,958 in payments to 0 healthcare providers, recorded across 8 transactions in the CMS Open Payments database. The primary manufacturer is ABLYNX NV.
Payment data is available from 2019 to 2019. In 2019, $100,958 was paid across 8 transactions to 0 doctors.
The most common payment nature for ALX-0171 is "Unspecified" ($100,958, 100.0% of total).
ALX-0171 is associated with 2 research studies, including "A randomized, double-blind, multicenter study to evaluate the efficacy and safety of ALX-0171 versus placebo, in addition to standard of care, in adults who have undergone hematopoietic stem cell tran" ($92,458).